ACE inhibitors, angiotensin receptor antagonists and bradykinin

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 1, 2000, Pages 27-29

  Schachter, Michael ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

ACE inhibitors; AT1 receptor antagonists; AT2 receptors; Bradykinin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL; DRUG ANTAGONISM; EDITORIAL; HUMAN; PHYSIOLOGY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN;

EID: 0034160611     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.005     Document Type: Review

References (36)

1. Margolius H. Kallikreins and kinins: molecular characteristics and cellular and tissue responses. Diabetes 1996; 45 (suppl 1): S14-S19.
2. Zisman LS. Inhibiting tissue angiotensin-converting enzyme: a pound of flesh without the blood. Circulation 1998; 98: 2788-2790.
3. Cleland JG, Morgan K. Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic research. Curr Opin Cardiol 1996; 11: 252-262.
4. Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf 1996; 15: 72-8.
5. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Saf 1998; 18: 171-188.
6. Semple PF. Putative mechanisms of cough after treatment with angiotensin-converting enzyme inhibitors. J Hypertens 1995; 13 (suppl 3): S17-S21.
7. Malini PL, Strocchi E, Zanardi M, Milani M, Ambrosioni E. Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. Lancet 1997; 350:15-18.
8. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angioedema. Lancet 1998; 351: 1693-1697.
9. Dell'Italia LJ, Oparil S. Bardykinin in the heart: friend or foe? Circulation 1999; 100: 2305-2307.
10. 2-receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31: 349-355.
11. Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of angiotensin-converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther 1996; 279: 703-712.
12. Bönner G. The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors. Drugs 1997; 54 (suppl 5): S23-S30.
13. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-1118.
14. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-1292.
15. Bouaziz H, Joulin Y, Safar M, Benetos A. Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition. Br J Pharmacol 1994; 113: 717-722.
16. Cheng CP, Onishi K, Ohte N, Suzuki M, Little WC. Functional effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol 1998; 31:1679-1686.
17. Su JB, Barbe F, Crozatier B, Campbell B, Campbell DJ, Hittinger L. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol 1999; 34: 700-710.
18. Davie AP, Dargie HJ, McMurray JJ. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation 1999; 100: 268-273.
19. Yang X-P, Liu Y-H, Scicli GM, Webb CR, Carretero O. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen deficient mice. Hypertension 1997; 30 (part 2): 735-740.
20. Emanueli C, Maetri R, Corradi D et al. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 1999; 100: 2359-2365.
21. Benzing T, Fleming I, Blaukat A, Müller-Esterl W, Busse R. Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999; 99: 2034-2040.
22. Chung O, Unger T. Angiotensin II receptor blockade and end-organ protection. Am J Hypertens 1999; 12: 150S-156S.
23. Kokkonen JO, Sarinen J, Kovanen PT. Angiotensin II formation in the human heart: an ACE or non-ACE mediated pathway? Ann Med 1998; 30 (suppl 1): S9-S13.
24. Takai S, Jin D, Sakaguchi M, Miyazaki M. Chymase-dependent angiotensin II formation in human vascular tissue. Circulation 1999; 100: 654-658.
25. Topol E. ACE inhibitors still the drug of choice for heart failure and more. Lancet 1999; 354: 1797.
26. Neutel JM. Safety and efficacy of angiotensin II receptor antagonists. Am J Cardiol 1999; 84 (suppl 2A): 13K-17K.
27. Birkenhager WH, de Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens 1999; 17: 873-881.
28. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Phystol 1996; 3 (suppl): S125-S131.
29. Nora EH, Munzenmaier DH, Hansen-Smith FM, Lombard JH, Greene AS. Localization of the ANG II type II receptor in the microcirculation of skeletal muscle. Am J Physiol 1998; 275: H1395-H1403.
30. Yang BC, Phillips MI, Mohuczy D et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18: 1433-1439.
31. 1-receptor gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995; 82: 10663-10667.
32. Weber MA. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists In the treatment of hypertension. Am J Hypertens 1999; 12: 189S-194S.
33. Tsutsumi Y, Matsubara H, Masaki H et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-935.
34. Searles CD, Harrison DG. The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice. J Clin Invest 1999; 104: 1013-1014.
35. Cha YJ, Pearson VE. Angioedema due to losartan. Ann Pharmacother 1999; 33: 936-938.
36. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 1999; 47: 111-114.